Analysis of preferential drug provision for patients with diabetes mellitus in the Stavropol Region
Year: 2025
Type: article
Study design: Observational Study
Abstract: The aim . To study the quantitative characteristics of the implementation of drug provision for beneficiaries with diabetes mellitus (DM) in the Stavropol Region in the period from 2020 to 2024. Materials and methods . The regulatory legal basis of the study was made up of legislative acts of the federal and regional levels on the organization of preferential drug provision (PDP). Clinical and epidemiological monitoring of DM was carried out according to the data of the State Register of DM for the Stavropol Region, data from the Regional Endocrinological Dispensary (Stavropol Region, Russia), as well as reports from executive authorities. Results . According to the clinical and epidemiological monitoring of DM in the Russian Federation in 2024, the prevalence of DM in the Stavropol Region did not exceed the average Russian indicators (rating 36). A decrease in the number of federal beneficiaries and an increase in the number of regional beneficiaries (with a predominance of DM type II) was noted. 10 municipalities where about 60% of patients with DM live were identified. Therapy for patients with DM type I is based on insulin therapy for 100% of patients. Therapy for patients with DM type II includes the use of insulin for 14,140 (20.63%) patients, oral hypoglycemic agents for 53,404 (77.88%) patients, and dietary adjustments for 1,025 (1.49%) people. Since 2024, in accordance with changes in the legislation of the Stavropol Region, all patients with DM are provided from general funds of the regional budget, with the exception of federal beneficiaries in Lermontov, who are provided at the expense of the program for the provision of necessary medicines (PNMs). The structure of expenditures from the federal and regional budgets for the purchase of funds for the treatment of DM is presented. The dynamics of the growth of expenses per one beneficiary with DM is shown. It should be noted that in 2024 there was an equalization of the amount of expenses per one federal and regional beneficiary. Conclusion. The results obtained can be used by other researchers to take solutions to improve the availability of drug provision for beneficiaries with DM both in the Stavropol Region and in other subjects of the Russian Federation.
Source: Pharmacy & Pharmacology
Authors: R. I. Yagudina, O. L. Listova
Institution: Sechenov University
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4414670461